High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

abstract：PURPOSE:To differentiate the antagonistic and agonistic effect of toremifene at the level of the hypothalamus-hypophysis axis a leutinizing hormone-releasing hormone (LHRH) test was performed during a phase II clinical trial. METHODS:In 15 postmenopausal patients with advanced breast cancer, follicle-stimulating hormo...

journal_title：Cancer chemotherapy and pharmacology

authors： Számel I,Hindy I,Budai B,Kangas L,Hajba A,Lammintausta R

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS:Patients were enrolled in a standard 3 + 3 design with lapatinib (L) 750, 1000...

journal_title：Cancer chemotherapy and pharmacology

authors： Lynce F,Wang H,Petricoin EF,Pohlmann PR,Smaglo B,Hwang J,He AR,Subramaniam DS,Deeken J,Marshall J,Pishvaian MJ

更新日期：2019-11-01 00:00:00

abstract：PURPOSE:Paclitaxel and docetaxel are two taxanes approved for the treatment of non-small-cell lung cancer (NSCLC). However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). The aim of our study was to evaluate the response to docetaxel in...

journal_title：Cancer chemotherapy and pharmacology

authors： Macedo-Pérez EO,Morales-Oyarvide V,Mendoza-García VO,Dorantes-Gallareta Y,Flores-Estrada D,Arrieta O

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:Amsalog, a derivative of 9-aminoacridine, is an inhibitor of topoisomerase II. Early studies of intravenous amsalog administered either once weekly, or daily for 3 days repeated every 3 weeks, showed that myelosuppression is the dose-limiting toxicity (DLT). Phase II studies showed only limited activity in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Fyfe D,Price C,Langley RE,Pagonis C,Houghton J,Osborne L,Woll PJ,Gardner C,Baguley BC,Carmichael J,Cancer Research Campaing Phase I\/II Trials Committee.

更新日期：2001-04-01 00:00:00

abstract：:The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC). This randomized, multicenter, phase II study compared the activities and safeties of the oral fluoropyrimidines, capecitabine and S-1, in breast cancer patients. METHODS:Patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto D,Iwase S,Tsubota Y,Ariyoshi K,Kawaguchi T,Miyaji T,Sueoka N,Yamamoto C,Teramoto S,Odagiri H,Kitamura K,Nagumo Y,Yamaguchi T

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:Folate receptor (FR) targeted drug conjugates were prepared by covalently attaching the vitamin folate, to the potent anticancer drug, mitomycin C (MMC). One such conjugate, called EC72, was synthesized with an intramolecular disulfide bond, and it was found to exhibit efficacious anti-tumor activity against FR...

journal_title：Cancer chemotherapy and pharmacology

authors： Reddy JA,Westrick E,Vlahov I,Howard SJ,Santhapuram HK,Leamon CP

更新日期：2006-08-01 00:00:00

abstract：PURPOSE:This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS:We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received placebo on day 1 and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lush RM,Patnaik A,Sullivan D,Papadopoulos KP,Trucksis M,McCrea J,Cerchio K,Li X,Stroh M,Selverian D,Orford K,Ebbinghaus S,Agrawal N,Iwamoto M,Wagner JA,Tolcher A

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS:Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early a...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Peyret T,Marchand M,Quartino A,Gosselin NH,Girish S,Allison DE,Jin J

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:Although treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors achieves a high response rate, a subset of melanoma patients with intrinsic and acquired resistance are insensitive to these therapeutics, so to improve melanoma therapy other target molecules need to be found. Here, we screene...

journal_title：Cancer chemotherapy and pharmacology

authors： Aida S,Sonobe Y,Yuhki M,Sakata K,Fujii T,Sakamoto H,Mizuno T

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:Experimental studies have shown that mitomycin C (MMC) acts synergistically with irinotecan. We evaluated the antitumor activity and toxicity of a combination of irinotecan and MMC in patients with metastatic colorectal cancer resistant to fluoropyrimidines. METHODS:Eligible patients had evidence of tumor prog...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Shirao K,Hyodo I,Arai Y,Denda T,Ambo T,Ohtsu A

更新日期：2003-08-01 00:00:00

abstract：:The mechanisms of cytotoxicity, cellular drug uptake, intracellular drug distribution, cellular pharmacokinetics, formation of arabinofuranosylcytosine triphosphate (ara-CTP), and DNA incorporation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC), a new lipophilic derivative of arabinofuranosylcytosine (ara-C)...

journal_title：Cancer chemotherapy and pharmacology

authors： Horber DH,Schott H,Schwendener RA

更新日期：1995-01-01 00:00:00

abstract：:Adriamycin, a broad-spectrum cytotoxic agent useful in cancer chemotherapy, is limited by a dose-dependent cardiomyopathy mediated in part by disruption of mitochondrial energetics. Hexakis(2-methoxyisobutyl isonitrile)technetium(I) (99mTc-SESTAMIBI) is a gamma-emitting radiopharmaceutical with myocellular accumulatio...

journal_title：Cancer chemotherapy and pharmacology

authors： Piwnica-Worms D,Chiu ML,Kronauge JF

更新日期：1993-01-01 00:00:00

abstract：BACKGROUND:The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. This phase II study was designed in order to explore the efficacy and safety of DCB regiment in this setting. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Kentepozidis N,Kotsakis A,Soultati A,Agelaki S,Christophylakis Ch,Agelidou M,Chelis L,Papakotoulas P,Vamvakas L,Zafiriou Z,Samonis G,Georgoulias V

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:Malignant rhabdoid tumors (MRT), although rare, are one of the most aggressive pediatric malignancies. Loss of INI1, a tumor suppressor gene and member of the SWI/SNF chromatin remodeling complex, is a recurrent genetic characteristic of these tumors and an important diagnostic marker. We have previously demons...

journal_title：Cancer chemotherapy and pharmacology

authors： Foster K,Wang Y,Zhou D,Wright C

更新日期：2009-04-01 00:00:00

abstract：:The cellular metabolism of 3'-amino-2',3'-dideoxycytidine (3'-NH2-dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside (ara-C) in cells that displayed dCydD activity (HeLa) and in cells that did not (L1210). Growth i...

journal_title：Cancer chemotherapy and pharmacology

authors： Mancini WR

更新日期：1992-01-01 00:00:00

abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

journal_title：Cancer chemotherapy and pharmacology

authors： Daoud SS,Juliano RL

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Patupilone (EPO906) is a novel potent microtubule stabilizer, which has been evaluated for cancer treatment. A novel physiologically based pharmacokinetics (PBPK) model was developed based on nonclinical data to predict the disposition of patupilone in cancer patients. METHODS:After a single intravenous dose (...

journal_title：Cancer chemotherapy and pharmacology

authors： Xia B,Heimbach T,Lin TH,He H,Wang Y,Tan E

更新日期：2012-06-01 00:00:00

abstract：:A total of 13 patients receiving bone marrow transplants (BMT) for treatment of different haematological diseases were investigated. Conditioning therapy preceding BMT consisted of fractionated total-body irradiation (12 Gy) and high-dose chemotherapy with cyclophosphamide (2 +/- 60 mg/kg). Patients stratified to be a...

journal_title：Cancer chemotherapy and pharmacology

authors： Ladner C,Ehninger G,Gey KF,Clemens MR

更新日期：1989-01-01 00:00:00

abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

journal_title：Cancer chemotherapy and pharmacology

authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:In this exploratory study, the effect of postprocedural flushing with crystalloids after oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) on platinum concentrations in peritoneal tissue, blood, and drain fluid was studied. Interpatient variability in oxaliplatin pharmacokinetics and the relat...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong LAW,Elekonawo FMK,Lambert M,de Gooyer JM,Verheul HMW,Burger DM,de Wilt JHW,Chatelut E,Ter Heine R,de Reuver PR,Bremers AJA,van Erp NP

更新日期：2020-07-01 00:00:00

abstract：:The effects of heat on intracellular accumulation of anthracyclines were investigated by laser flow cytometry analysis. Sarcoma-180 cells were exposed to Adriamycin (ADM), epirubicin (EPIR), daunomycin (DM), THP-Adriamycin (THP), ME-2303 (ME) and KRN-8602 (KRN) at 37 degrees C and at higher temperatures. There was a d...

journal_title：Cancer chemotherapy and pharmacology

authors： Sakaguchi Y,Maehara Y,Inutsuka S,Takahashi I,Yoshida M,Emi Y,Baba H,Sugimachi K

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated. METHODS:Patients with hepatocellular carcinoma no longer amenable to established forms o...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno H,Okada S,Okusaka T,Ikeda M,Kuriyama H

更新日期：2002-02-01 00:00:00

abstract：:Characterization of the pharmacokinetics of 2-FLAA has been completed in seven patients receiving 18 or 25 mg/m2 daily X 5 of 2-FLAMP over 30 min. Assuming 2-FLAMP was instantaneously converted to 2-FLAA, the plasma levels of 2-FLAA declined in a biexponential fashion. Computer fitting of the plasma concentration-time...

journal_title：Cancer chemotherapy and pharmacology

authors： Hersh MR,Kuhn JG,Phillips JL,Clark G,Ludden TM,Von Hoff DD

更新日期：1986-01-01 00:00:00

abstract：:Mitoxantrone, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride, a new antitumor agent was evaluated in nine cancer patients as part of a phase I trial. In general, the drug was well tolerated. Leukopenia was the dose-limiting toxic effect. Mild to moderate leukopenia...

journal_title：Cancer chemotherapy and pharmacology

authors： Alberts DS,Griffith KS,Goodman GE,Herman TS,Murray E

更新日期：1980-01-01 00:00:00

abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

journal_title：Cancer chemotherapy and pharmacology

authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

journal_title：Cancer chemotherapy and pharmacology

authors： Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

更新日期：2001-05-01 00:00:00

abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

journal_title：Cancer chemotherapy and pharmacology

authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

更新日期：2019-03-01 00:00:00

abstract：:A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomson AH,Daly M,Knepil J,Harden P,Symonds P

更新日期：1996-01-01 00:00:00